Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCTV01E-2
- Development stage
- Phase 2
- Lead developer
- Sinocelltech
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
SCTV01E-2 is a tetravalent recombinant protein-based COVID-19 vaccine designed to provide broad protection against multiple SARS-CoV-2 variants. It contains the trimeric spike extracellular domain (S-ECD) proteins from four different SARS-CoV-2 variants, formulated with a squalene-based oil-in-water adjuvant. The vaccine elicits robust neutralizing antibody responses, particularly against Omicron EG.5 and XBB.1 subvariants, and has demonstrated a favorable safety profile in clinical trials with no serious adverse events reported. Its mechanism of action involves inducing an immune response targeting the spike protein of SARS-CoV-2, thereby inhibiting viral entry into host cells[1][6].
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on SCTV01E-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCTV01E-2.